Annual Congress Copenhagen 2005

Saturday, 17.09.2005
Sunday, 18.09.2005
Monday, 17.09.2005
Tuesday, 20.09.2005
Wednesday, 21.09.2005

Citations should be made in the following way: Authors. Title. Eur Respir J 2005; 26: Suppl. 49, abstract number.

Material from 2005:

4063 Abstracts
739 Slide presentations
213 Webcasts
93 Handouts

Material from 2005: Show

Bronchodilators with and without corticosteroids

Thematic Poster Session
Chairs: S. Centanni (Milan, Italy), G. Brusselle (Ghent, Belgium)

Download all media

Expression and functional involvement of muscarinic receptor 3 (M3) in human lung fibroblasts in COPD M. Profita, R. Di Giorgi, L. Siena, L. Riccobono, A. Bonanno, M. Piper, E. Pace, G. Bonsignore, M. Gjomarkaj (Palermo, Italy; Ingelheim, Germany)
Tiotropium bromide inhibits acetylcholine-induced proliferation of fibroblasts and myofibroblasts in vitro N. I. Chaudhary, J. E. Park, G. Zissel, J. Muller-Quernheim, M. P. Pieper (Biberach, Freiburg, Germany)
New researches on teratogenic and embryogenotoxic effects of tiotropium A. Januskevicius, A. Valiulis, P. Gaidelis, A. Brukstus (Vilnius, Lithuania)
*Indacaterol, a novel 24-hour β₂-agonist, demonstrates a long duration of action and fast onset in vitro* and in vivo in the guinea pig** C. A. Lewis, L. Jordan, D. Wyss, D. Bayley, J. Maas, C. Battram (Horsham, United Kingdom)
Detection of bronchospasmolytic effects of clenbuterol and butylscopolamine in RAO horses by means of impulse oscillometry system (IOS) C. C. Klein, H. J. Smith (Bad Langensalza, Berlin, Germany)
A pMDI formulation of levosalbutamol produces an equivalent bronchodilator response as racemic salbutamol at half the dose A. Jantikar, B. Brashier, A. Raghupathy, T. Bal, P. Mahadik, P. Gokhale, J. Gogtay, S. S. Salvi (Pune, Mumbai, India)
The effect of formoterol in elderly COPD patients U. Yegen, D. Till, G. P. Geba (East Hanover, United States Of America; Horsham, United Kingdom)
Tolerance to bronchodilation is not overcome by high dose salbutamol S. Haney, R. J. Hancox (Hamilton, New Zealand)
The bronchodilator response to ipratropium is not affected by regular β-agonist use S. Haney, R. J. Hancox (Hamilton, New Zealand)
Intermittent treatment with budesonide/formoterol in an allergic rat model C. Brange, A. Smailagic, A. H. Jansson, H. Zhao, X. Zhao, A. Miller-Larsson, R. Andersson, X. Wang (Lund, Sweden)
Budesonide and formoterol inhibit bronchial epithelial cell-mediated eosinophil superoxide production S. Persdotter, M. Lindahl, M. Malm-Erjefält, K. von Wachenfeldt, S. H. Korn, T. Stevens, A. Miller-Larsson (Lund, Sweden)
Comparison between fluticasone and salmeterol plus fluticasone on functional responses and sputum eosinophilia induced by allergen challenge F. L. Dente, E. Garbella, A. DiFranco, S. Cianchetti, E. Masino, P. Paggiaro (Pisa, Italy)
Glucocorticoid-induced neutrophil survival is potentiated by β₂-agonists H. Perttunen, E. Moilanen, X. Zhang, H. Kankaanranta (Tampere, Finland)
Benefit of flexible budesonide/formoterol dosing against bronchoconstriction requires adjustment of both components X. Wang, A. H. Jansson, A. Smailagic, C. Brange, J. D. Taylor, D. S. Siberstein (Lund, Sweden)
lnhaled long-acting beta-agonists as an inhaled corticosteroid-sparing agent for chronic asthma in adults H. Powell, P. G. Gibson, F. M. Ducharme (Newcastle, Australia; Montreal, Canada)
*Salmeterol and beclomethasone dipropionate versus* higher dose beclomethasone dipropionate in asthma patients** I. J. Stankovic, T. A. Pejcic, M. H. Rancic, D. D. Djordjevic, L. M. Ristic (Nis, Serbia And Montenegro)
Single inhaler therapy (SiT) with budesonide/formoterol (BUD/FM) is effective in asthma control S. Loukides, M. Papageorgiou, A. Karokis, E. Zervas, A. Christodoulopoulou, N. Papageorgiou, M. Gaga (Athens, Greece)
Is the combination of long-acting β₂-agonists (LABA) and inhaled steroids (ICS) superior to higher ICS dose in children and adults with persistent asthma? I. R. Greenstone, M. N. Ni Chroinin, X. Zhang, F. M. Ducharme (Montreal, Canada; Norwich, United Kingdom)
*Combination of inhaled corticosteroids (ICS) and long-acting β2-agonists (LABA) versus* similar ICS dose in children and adults with persistent asthma** M. N. Ni Chroinin, I. R. Greenstone, X. Zhang, F. M. Ducharme (Norwich, United Kingdom; Montreal, Canada)
A pilot study comparing tiotropium to salmeterol plus fluticasone in moderate COPD E. Bateman, M. Van-Dyk, A. Chang, A. Sagriotis (Cape Town, Johannesburg, South Africa; Ingelheim, Germany)